Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: A prospective study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 1036-1043

  Qi, Xingshun ^a   Zhang, Cheng ^a   Han, Guohong ^a   Zhang, Wei ^a   He, Chuangye ^a   Yin, Zhanxin ^a   Liu, Zhiwei ^a   Bai, Wei ^a   Li, Ruijun ^a   Bai, Ming ^a   Yang, Zhiping ^a   Wu, Kaichun ^a,b   Fan, Daiming ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Budd Chiari syndrome; JAK2V617F mutation; Portal vein thrombosis; Prevalence

Indexed keywords

ADULT; ARTICLE; BUDD CHIARI SYNDROME; CHINESE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GROUPS BY AGE; HUMAN; LIVER CIRRHOSIS; MALE; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT;

EID: 84861465023     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07040.x     Document Type: Article

References (32)

1. Valla DC. Primary Budd-Chiari syndrome. J. Hepatol. 2009; 50: 195-203.
2. Primignani M. Portal vein thrombosis, revisited. Dig. Liver Dis. 2010; 42: 163-70.
3. Valla D, Casadevall N, Huisse MG etal. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063-9.
4. Valla D, Casadevall N, Lacombe C etal. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann. Intern. Med. 1985; 103: 329-34.
5. Chait Y, Condat B, Cazals-Hatem D etal. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br. J. Haematol. 2005; 129: 553-60.
6. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007; 7: 673-83.
7. Baxter EJ, Scott LM, Campbell PJ etal. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
8. Kralovics R, Passamonti F, Buser AS etal. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005; 352: 1779-90.
9. Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment. Pharmacol. Ther. 2011; 33: 1087-103.
10. Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am. J. Clin. Pathol. 2010; 134: 82-5.
11. Darwish Murad S, Valla DC, de Groen PC etal. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-8.
12. Valla DC. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J. Gastroenterol. Hepatol. 2004; 19: S204-11.
13. Colaizzo D, Amitrano L, Guardascione MA, Balzano A, Margaglione M. Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis. Eur. J. Gastroenterol. Hepatol. 2008; 20: 245-6.
14. Xavier SG, Gadelha T, Pimenta G etal. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig. Dis. Sci. 2010; 55: 1770-7.
15. Han G, Qi X, He C etal. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J. Hepatol. 2011; 54: 78-88.
16. Wang ZG. Recognition and management of Budd-Chiari syndrome. Experience with 143 patients. Chin. Med. J. 1989; 102: 338-46.
17. Yang XL, Cheng TO, Chen CR. Successful treatment by percutaneous balloon angioplasty of Budd-Chiari syndrome caused by membranous obstruction of inferior vena cava: 8-year follow-up study. J. Am. Coll. Cardiol. 1996; 28: 1720-4.
18. Wu T, Wang L, Xiao Q etal. Percutaneous balloon angioplasty of inferior vena cava in Budd-Chiari syndrome-R1. Int. J. Cardiol. 2002; 83: 175-8.
19. Xu K, He FX, Zhang HG etal. Budd-Chiari syndrome caused by obstruction of the hepatic inferior vena cava: immediate and 2-year treatment results of transluminal angioplasty and metallic stent placement. Cardiovasc. Intervent. Radiol. 1996; 19: 32-6.
20. Xu K, Feng B, Zhong H etal. Clinical application of interventional techniques in the treatment of Budd-Chiari syndrome. Chin. Med. J. 2003; 116: 609-15.
21. Zhang CQ, Fu LN, Xu L etal. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J. Gastroenterol. 2003; 9: 2587-91.
22. Xiaoming Z, Zhonggao W. Interventional or semi-interventional treatment for Budd-Chiari syndrome. Chin. Med. Sci. J. 2003; 18: 111-15.
23. Xu PQ, Ma XX, Ye XX etal. Surgical treatment of 1360 cases of Budd-Chiari syndrome: 20-year experience. Hepatobiliary Pancreat. Dis. Int. 2004; 3: 391-4.
24. Qiao T, Liu CJ, Liu C, Chen K, Zhang XB, Zu MH. Interventional endovascular treatment for Budd-Chiari syndrome with long-term follow-up. Swiss Med. Wkly 2005; 135: 318-26.
25. Dang XW, Xu PQ, Ma XX. Radical resection of pathological membrane for Budd-Chiari syndrome. Hepatobiliary Pancreat. Dis. Int. 2007; 6: 157-60.
26. Li T, Zhai S, Pang Z etal. Feasibility and midterm outcomes of percutaneous transhepatic balloon angioplasty for symptomatic Budd-Chiari syndrome secondary to hepatic venous obstruction. J. Vasc. Surg. 2009; 50: 1079-84.
27. Xue H, Li YC, Shakya P, Palikhe M, Jha RK. The role of intravascular intervention in the management of Budd-Chiari syndrome. Dig. Dis. Sci. 2010; 55: 2659-63.
28. Li XM, Wei YF, Hao HL etal. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am. J. Hematol. 2002; 71: 11-14.
29. Lin GL, Xu PQ, Qi H, Lian JH, Zheng H, Dang XW. Relations of Budd-Chiari syndrome to prothrombin gene mutation. Hepatobiliary Pancreat. Dis. Int. 2004; 3: 214-18.
30. Zocco MA, Di Stasio E, De Cristofaro R etal. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J. Hepatol. 2009; 51: 682-9.
31. Xu X, Zhang Q, Luo J etal. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 2007; 109: 339-42.
32. Xijing Hospital. Introduction. Cited March 2011. Available from URL: